This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Domanski, P. J. Articles by Patti, J. M. Search for Related Content PubMed PubMed Citation Articles by Domanski, P. J. Articles by Patti, J. M.

Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A Expressed by Staphylococcus aureus

Inhibitex, Inc., Alpharetta, Georgia,¹ LA Biomedical Research, Torrance, California²

Received 4 October 2004/ Returned for modification 1 December 2004/ Accepted 14 March 2005

We report the humanization and characterization of monoclonal antibody (MAb) T1-2 or tefibazumab, a monoclonal antibody that recognizes clumping factor A expressed on the surface of Staphylococcus aureus. We demonstrate that the binding kinetics of MAb T1-2 is indistinguishable compared to that of its murine parent. Furthermore, MAb T1-2 is shown to enhance the opsonophagocytic uptake of ClfA-coated latex beads, protect against an intravenous challenge in a prophylactic model of rabbit infective endocarditis, and enhance the efficacy of vancomycin therapy in a therapeutic model of established infective endocarditis.

Editor: F. C. Fang

This article has been cited by other articles:

• Bekeredjian-Ding, I., Inamura, S., Giese, T., Moll, H., Endres, S., Sing, A., Zahringer, U., Hartmann, G. (2007). Staphylococcus aureus Protein A Triggers T Cell-Independent B Cell Proliferation by Sensitizing B Cells for TLR2 Ligands. J. Immunol. 178: 2803-2812 [Abstract] [Full Text]  
• Hetherington, S., Texter, M., Wenzel, E., Patti, J. M., Reynolds, L., Shamp, T., Swan, S. (2006). Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.. Antimicrob. Agents Chemother. 50: 3499-3500 [Abstract] [Full Text]  
• Weems, J. J. Jr., Steinberg, J. P., Filler, S., Baddley, J. W., Corey, G. R., Sampathkumar, P., Winston, L., John, J. F., Kubin, C. J., Talwani, R., Moore, T., Patti, J. M., Hetherington, S., Texter, M., Wenzel, E., Kelley, V. A., Fowler, V. G. Jr. (2006). Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia.. Antimicrob. Agents Chemother. 50: 2751-2755 [Abstract] [Full Text]  
• Pourmand, M. R., Clarke, S. R., Schuman, R. F., Mond, J. J., Foster, S. J. (2006). Identification of Antigenic Components of Staphylococcus epidermidis Expressed during Human Infection.. Infect. Immun. 74: 4644-4654 [Abstract] [Full Text]  
• Kelly-Quintos, C., Cavacini, L. A., Posner, M. R., Goldmann, D., Pier, G. B. (2006). Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine.. Infect. Immun. 74: 2742-2750 [Abstract] [Full Text]